Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications ...

This study evaluated copanlisib plus nivolumab in adults with advanced solid tumors. Patients and Methods: In this phase Ib, nonrandomized, open-label, dose-escalation study, patients received ...

Endoscopic augmentation of the lower oesophageal sphincter using hydrogel implants for the treatment of gastro-oesophageal reflux disease IPG222 27 June 2007 27 June 2007 Carmustine implants and ...

Most patients have mild skin reactions, while severe (grade 3-4) toxicities are found in a low proportion of patients (5.8% for the ipilimumab + nivolumab combination, even lower values for anti-PD-1 ...

and nivolumab after the radiation. After clinical deterioration within 4 weeks of starting checkpoint therapy, the patient showed a marked increase in T2 changes outside the radiation field.

Among the general data from the CheckMate 649 trial (NCT02872116) of nivolumab plus chemotherapy, he touched on the continuing debate of using combined positive score (CPS) of PD-L1 as a cut-off, as ...

The FDA is conducting a priority review of nivolumab plus ipilimumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer. The FDA has accepted a ...

Bone-Derived Hormone Predicts Diabetic Kidney Disease Risk Elevated serum fibroblast growth factor 23 levels at baseline are linked to a 29% increased risk for diabetic kidney disease, a recent ...